Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-03-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于变更公司电子邮箱的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (439 characters) about the change of the company's electronic email address. It does not contain any financial data, report content, or regulatory certifications. It is an operational update related to contact information, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Regulatory Filings that require substantive content. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-03-22 Chinese
东海证券股份有限公司关于昆药集团股份有限公司2022年度募集资金存放与实际使用情况专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Donghai Securities regarding the 2022 annual status of raised funds (募集资金) for Kunming Pharmaceutical Group Co., Ltd. It includes extensive information on the storage, usage, and management of funds raised in 2013 and 2015, with references to regulatory guidelines and verification by an accounting firm (Ernst & Young Hua Ming). The document contains tables showing the amounts raised, usage progress, project investment details, and audit opinions on the fund usage. It is a specialized verification report on the use and management of raised capital for the year 2022, not a general annual report or earnings release. It is not a simple announcement or certification but a substantive report with financial and regulatory compliance details. This fits the category of Capital/Financing Update (CAP), as it focuses on fundraising and capital usage updates for the company.
2023-03-22 Chinese
昆药集团2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2022 from Kunming Pharmaceutical Group Co., Ltd. It details the independent directors' duties, attendance at board and shareholder meetings, their opinions on related party transactions, external guarantees, use of raised funds, remuneration, stock incentive plans, appointment of auditors, dividend distribution, asset impairment, information disclosure, and internal control execution. The content is a detailed report on the independent directors' work and opinions for the year, which is a typical form of a management or supervisory report rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on governance and oversight activities by independent directors. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board activities and management oversight, especially changes or reports from directors. The document length (6577 characters) and detailed content confirm it is a full report, not a brief announcement or certification.
2023-03-22 Chinese
昆药集团十届十三次董事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the 13th meeting of the 10th board of directors held on March 21, 2023. The resolutions include approval of various 2022 annual reports such as the president's work report, board work report, audit and risk control committee report, independent directors' report, internal control evaluation and audit reports, annual report and summary, social responsibility report, financial settlement report, profit distribution plan, fundraising usage report, asset impairment and disposal, 2023 financing quota, capital expenditure plan, personnel performance and remuneration matters, and stock repurchase related to the 2021 restricted stock incentive plan. Many reports are noted as fully published on the Shanghai Stock Exchange website, indicating this document is a formal announcement of board decisions rather than the reports themselves. The document is under 5,000 characters and primarily serves to announce board resolutions and voting results, not to present the full reports or detailed financial data. Therefore, it fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-03-22 Chinese
昆药集团关于2023年度融资额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's financing limit proposal for the year 2023. It details the planned financing amounts, purposes, and authorization requests for the board and shareholders. The content focuses on financing activities and capital structure changes, without presenting financial statements or results. The document length is short (1404 characters) and it is not a report but an announcement of financing plans and authorizations. Therefore, it fits the category of Capital/Financing Update (CAP).
2023-03-22 Chinese
昆药集团2022年度审计报告
Regulatory Filings
2023-03-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.